|Posted by gulseth.michael on September 25, 2018 at 3:45 PM||comments (2)|
by Shelby Rabenberg, Pharm D Student Pharmacist
Edited by Michael P. Gulseth, Pharm. D., BCPS, FASHP
The scope of anticoagulation therapy is slowly changing due to the emergence of direct oral anticoagulants (DOACs). DOACs eliminate several problems that are seen with warfarin including need for frequent INR monitoring, dietary considerations and pre-operative bridging. Even though routine anticoagulation effect monitoring of DOACs is deemed as unnecessary, there ...Read Full Post »
|Posted by gulseth.michael on June 20, 2018 at 5:25 PM||comments (6)|
By Darren R Kueter, Student Pharmacist
Edited by Michael P. Gulseth, Pharm. D., BCPS, FASHP
PCC (prothrombin complex concentrate) is a reversal agent that can be utilized in the event of acute major bleeding or the need for urgent surgery in patients that are taking vitamin K antagonists such as warfarin. PCC does have many advantages over FFP (fresh frozen plasma) for the reversal of bleeding events. These advantages include quicker reconstitution (no th...Read Full Post »
|Posted by gulseth.michael on May 10, 2018 at 10:00 AM||comments (1)|
One thing I love about my job is it never gets boring…….
Unless you live under a rock, I am sure you are aware the first specific reversal agent for factor Xa inhibitors has been approved. The full package insert can be found at: https://www.andexxa.com/prescribing-information/
Now, as an antithrombotic pharmacist, I’ve been following the development of this agent very closely for years. Here is a list of issues I am immensely intereste...Read Full Post »
|Posted by gulseth.michael on April 29, 2017 at 12:40 AM||comments (0)|
I recently partnered with Stago to create a new, on demand activity talking about contemporary laboratory issues with DOAC therapy. It is called "Direct Oral Anticoagulant Screening and Measurement for Challenging Patient Cases" and can be found at this link:
I do realize pharmacists cannot get CE for this, but other professionals can. With that said, these are critical...Read Full Post »
|Posted by gulseth.michael on April 25, 2017 at 2:20 PM||comments (57)|
Soon after the advent of direct oral anticoagulation therapy, we were confronted with what should we do in patients with new or history of bariatric surgery. At our hospital, we quickly moved away from them in this population, but it is a deficient topic that in all of the DOAC package labels.
Thankfully, a recent, excellent review was pulblished on this topic:
Martin KA, Lee CR, Farrell TM, Moll S. Oral Anticoagulant Use After Bariatric Surgery: A Literature Rev...Read Full Post »
|Posted by gulseth.michael on April 25, 2017 at 12:25 AM||comments (0)|
I keep running into a lack of understanding of the effects of DOACs on traditional labs. I want to summarize, and keep this simple:
Dabigatran will modestly prolong aPTT at therapeutic and high levels. If normal, patient could still have therapeutic levels. Best lab to confirm low dabigatran levels for many is thrombin time. If the thrombin time is measurable or normal, patient likely has very low dabigatran levels.
Rivaroxaban typically causes a significant...Read Full Post »
|Posted by gulseth.michael on March 16, 2017 at 7:00 AM||comments (0)|
HIT; it is the anticoagulation topic that you must know if you practice in hospitals in anticoagulation. I never cease to be amazed by the errors and mistakes that can happen when caring for HIT patients. I just want to pass along a few tips based on practical experience:
1. PF4 antibody testing is great if you remember it is very sensitive, but not very specific. Why? It tests for antibodies that bind to heparin/PF4 complexes. So, if the test is negative, you likely ...Read Full Post »
|Posted by gulseth.michael on March 13, 2017 at 11:50 AM||comments (0)|
While waiting for a doctor to call back so I can stop an un-needed heparin drip, I felt like writing a few miscellaneous thoughts on my mind:
1. We had another rivaroxaban to heparin transition yesterday. In this case, patient had acute PE and went into AKI while on rivaroxaban. 36 hours after a last dose of rivaroxaban, they drew a rivaroxaban level. It was 201 ng/ml, likely at a therapeutic level. Patient had a chest tube placed at that time (the reas...Read Full Post »
|Posted by gulseth.michael on March 8, 2017 at 1:30 PM||comments (0)|
Recently, there was a good article in AJHP on dealing with transitions from oral Xa inhibitors to heparin. You can read it at AJHP 2016; 73:2037-41
This has piqued a lot of my interest in this subject since we actively use novel drug levels like dabigatran, rivaroxaban, and apixaban levels. We have published on this in the past. See: http://www.ajhp.org/content/early/2017/02/21/ajhp160168
Recently, I have been seeing a lack of understanding on how to hand...Read Full Post »
|Posted by gulseth.michael on February 17, 2017 at 11:30 AM||comments (0)|
Excited to announce the realease of the new, 2017 ISMP Medication Safety Self-Assessment for Antithrombotic Therapy. I would strongly encourage all practitioners who work in health-systems to review these new guidelines so we can keep our patients safe. They do cover direct acting oral anticoagulants.
Thank you, as always, to the leadershp shown by ISMP!
Michael P. Gusleth, Phar...Read Full Post »